RS-2024-00333115

Development of the candidate for Standard Treatment-Resistant/ Refractory Prostate Cancer through direct inhibition of XBP1s, a Mediator of ER stress

JW C&C Research Laboratories

JW C&C Research Laboratories

ONCOLOGY | **Candidate**

Product Type	Chemical- Small Molecule
Indication	Metastatic Castration-resistant prostate cancer (mCRPC) XBP1s-dependent SoC resistant Solid cancer
Target	X-Box-binding Protein 1 splicing form (XBP1s)
MoA(Mechanism of Action)	Directly binds to XBP1s and induces its protein degradation → Downregulates target gene expression, Leading to inhibition of cell growth
Competitiveness	• Novel first-in-class inhibitor by directly binding to XBP1s protein • Strong anti-tumor effects against resistant/refractory patients to mCRPC SoC (ARi) which has highly unmet medical needs • Superior efficacy and safety over MKC-8866 (IRE1α RNase inhibitor, Phase 2)
Development Stage	Candidate
Route of Administration	Oral Administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund